{"id":94876,"date":"2013-11-07T13:47:13","date_gmt":"2013-11-07T18:47:13","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/foundation-medicine-is-part-of-an-effort-to-advance-new-clinical-trial-design-in-lung-cancer.php"},"modified":"2013-11-07T13:47:13","modified_gmt":"2013-11-07T18:47:13","slug":"foundation-medicine-is-part-of-an-effort-to-advance-new-clinical-trial-design-in-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/foundation-medicine-is-part-of-an-effort-to-advance-new-clinical-trial-design-in-lung-cancer.php","title":{"rendered":"Foundation Medicine is part of an effort to advance new clinical trial design in lung cancer"},"content":{"rendered":"<p><p>    By Chris    Reidy\/Globe Staff\/November 7, 2013  <\/p>\n<p>      Foundation      Medicine Inc., a Cambridge cancer diagnostics start-up      that has attracted high-profile financial backers such as      Microsoft Corp. founder Bill Gates and Russian billionaire      Yuri Milner, said Thursday that it has partnered witha      coalitionof groups to advancea revolutionary      newclinical trialdesignfor lung cancer.    <\/p>\n<p>    The partnership includes Friends of Cancer Researchas    well asfederal health and regulatory    agencies,pharmaceutical companies,multiple    cooperative groups,andpatient advocacy    organizations. The goal of the partnership    istodevelop the clinical trial    designfortheMaster    Protocolstudyin patients withsquamous cell    carcinoma of the lung,acommon subtype of non-small    cell lung cancer, the leading cancer killer of men and women in    the US, the company said in a     press release.  <\/p>\n<p>    In a statement, Ellen V. Sigal, chairperson and founder of    Friends of Cancer Research, said: FoundationMedicines    comprehensive genomic platform is a critical component of the    trial design, which requires the ability to identify all    classes of genomic alterations across many different genes from    one patient tissue sample, which ultimately informs the drug or    drugs each patient will receive in the trial. This    revolutionary clinical trial will provide a new perspective on    our current system, saving time, money and lives. Our vision is    that the concept and design of the Master Protocol study will    serve as a model for future trials to accelerate the way new    targeted therapies are developed and moved through the    regulatory process to patients.  <\/p>\n<p>     Copyright 2013 Globe    Newspaper Company.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read the original here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/feeds.boston.com\/c\/35022\/f\/646898\/s\/336ad297\/sc\/14\/l\/0L0Sboston0N0Cbusiness0Cnews0C20A130C110C0A70Cfoundation0Emedicine0Epart0Eeffort0Eadvance0Enew0Eclinical0Etrial0Edesign0Elung0Ecancer0C8YH9zawYubZAlJNxHA32FL0Cstory0Bhtml\/story01.htm\" title=\"Foundation Medicine is part of an effort to advance new clinical trial design in lung cancer\">Foundation Medicine is part of an effort to advance new clinical trial design in lung cancer<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> By Chris Reidy\/Globe Staff\/November 7, 2013 Foundation Medicine Inc., a Cambridge cancer diagnostics start-up that has attracted high-profile financial backers such as Microsoft Corp. founder Bill Gates and Russian billionaire Yuri Milner, said Thursday that it has partnered witha coalitionof groups to advancea revolutionary newclinical trialdesignfor lung cancer. The partnership includes Friends of Cancer Researchas well asfederal health and regulatory agencies,pharmaceutical companies,multiple cooperative groups,andpatient advocacy organizations <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/foundation-medicine-is-part-of-an-effort-to-advance-new-clinical-trial-design-in-lung-cancer.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-94876","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/94876"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=94876"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/94876\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=94876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=94876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=94876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}